ARRP-16/19 proteins have become the focus of many studies in the past few years as a result of their discovery as potent inhibitors of PP2A (Gharbi-Ayachi et al., 2010; Mochida et al., 2010), and their role in several cancer types such as HCC (Song et al., 2014), human glioma (Jiang et al., 2016), and AML (Mäkelä et al., 2019). This evidence concerns the gene PTPA and hepatocellular carcinoma.